Endocyte (NASDAQ:ECYT) is a biopharmaceutical company targeting cancer with a unique small molecule drug conjugate (SMDC) and companion imaging platform. Despite the stock price rising to an all time high last week, Endocyte is still undervalued. To provide you with sufficient background information, I suggest you read my previous article on Endocyte before reading my valuation model presented in this article. The purpose of this article is to determine the present value of Endocyte using discounted cash flow (DCF) analysis. Although Endocyte has multiple programs in clinical development, I will only discuss the most advanced: vintafolide (EC145)/etarfolatide (EC20) [currently in a phase III clinical trial (PROCEED) for platinum resistant ovarian cancer (PROC) and a phase II clinical trial...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|
|PRO Top long ideas returned 21.7% in 2016**|